Current Report Filing (8-k)
15 March 2023 - 10:01PM
Edgar (US Regulatory)
0001710340 false 0001710340 2023-03-15
2023-03-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
March 15, 2023
Date
of Report (Date of earliest event reported)
ETON PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
001-38738 |
|
37-1858472 |
|
(State |
|
(Commission |
|
(I.R.S.
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
Number) |
21925 W. Field Parkway,
Suite 235
Deer Park,
Illinois
60010-7208
(Address of principal executive offices) (Zip code)
(847)
787-7361
(Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
ETON |
|
NASDAQ Global Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events.
On
March 15, 2023, Eton Pharmaceuticals, Inc. issued a press release
announcing that it had acquired the rare disease product candidate
ET-600 from Tulex Pharmaceuticals.
ET-600
is an innovative product candidate under development for the
treatment of an endocrinology condition that is estimated to impact
less than 5,000 pediatric patients in the United States. Eton
expects to submit a New Drug Application (NDA) for the product to
the U.S. Food and Drug Administration in the second quarter of
2024, which could allow for an approval and launch of the product
in early 2025.
A
copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
March 15, 2023 |
By: |
/s/
James R. Gruber |
| |
|
James
R. Gruber |
| |
|
Chief
Financial Officer and Secretary |
|
|
|
(Principal
Financial Officer) |
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2023 to Jun 2023
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Jun 2022 to Jun 2023
